OPNT OPNT

Opiant Pharmaceuticals Stock Price

20.08
0.00 (0.0%)
Upgrade to Real-Time
Regular Market
20.08
Volume 79,583
Bid Price 20.07
Ask Price 20.09
News -
Day High 20.20

Low
7.34

52 Week Range

High
37.7114

Day Low 20.07
Company Name Stock Ticker Symbol Market Type
Opiant Pharmaceuticals Inc OPNT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 20.08 13:09:39
Open Price Low Price High Price Close Price Prev Close
20.07 20.07 20.20 20.08
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
463 79,583 $ 20.11 $ 1,600,283 - 7.34 - 37.7114
Last Trade Time Type Quantity Stock Price Currency
13:20:49 500 $ 20.08 USD

Period:

Draw Mode:

Opiant Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 103.77M 5.17M 4.91M $ 40.73M $ -25.46M 0.31 -3.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 10.30%

more financials information »

Opiant Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OPNT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week20.0920.2420.0020.08106,000-0.01-0.05%
1 Month9.8320.509.1219.55170,35510.25104.27%
3 Months11.4920.509.1218.3166,8878.5974.76%
6 Months14.8820.509.1216.6042,6545.2034.95%
1 Year25.0037.71147.3421.3065,490-4.92-19.68%
3 Years13.2537.71146.787816.6256,6236.8351.55%
5 Years33.7337.71146.787817.1047,055-13.65-40.47%

Opiant Pharmaceuticals Description

Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.